CorMedix Inc. (CRMD) Sees Significant Increase in Short Interest

CorMedix Inc. (NYSEAMERICAN:CRMD) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,715,967 shares, an increase of 28.2% from the October 13th total of 2,118,383 shares. Approximately 4.9% of the shares of the company are short sold. Based on an average daily trading volume, of 944,548 shares, the days-to-cover ratio is currently 2.9 days.

CorMedix (NYSEAMERICAN:CRMD) opened at $0.50 on Friday. CorMedix has a 52-week low of $0.32 and a 52-week high of $2.48.

Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of CorMedix from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Monday, August 14th. HC Wainwright set a $4.00 price target on shares of CorMedix and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Rodman & Renshaw lowered their price target on shares of CorMedix from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 10th.

A number of institutional investors and hedge funds have recently bought and sold shares of CRMD. Vanguard Group Inc. boosted its position in CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 35,148 shares during the last quarter. Elliott Management Corp raised its stake in CorMedix by 177.8% during the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock worth $1,785,000 after purchasing an additional 2,666,668 shares during the period. Susquehanna International Group LLP raised its stake in CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 2,085,670 shares during the period. Finally, Sabby Management LLC purchased a new position in CorMedix during the second quarter worth about $1,818,000.

TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

What are top analysts saying about CorMedix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CorMedix Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit